The 14,15-DHET is a representative metabolite of soluble epoxide hydrolase (sEH)-mediated metabolism of EETs, generated by arachidonic acid epoxygenase activity of cytochromes P450 (CYPs) 2C and 2J. This competitive ELISA kit with an HRP system has been used to determine 14,15-DHET levels in biological samples (tissue, plasma and urine) and cell culture media. Using the 14,15-DHET ELISA, strong positive correlation has been discovered with 14,15-DHET levels on hypertension and brain injury and stroke, and EET levels on a metastatic phenotype of carcinoma cells and insulin resistance. Next generation hypertension drug discoveries have been carried out at several laboratories. Each kit for a 96-well plate is good for triplicate analyses of up to 24 samples.

14，15-DHET是可溶性環氧化物水解酶（sEH）介導的代謝的代表性代謝物 EETs，由細胞色素P450（CYPs）2C和2J的花生四烯酸環氧合酶活性產生。

這種帶有HRP系統的艾美捷Detroit R&D競爭性ELISA試劑盒已用于測定生物樣品（組織，血漿和尿液）和細胞培養基中的14，15-DHET水平。使用 14，15-DHET ELISA，已發現 14，15-DHET 水平與高血壓、腦損傷和中風以及 EET 水平與癌細胞轉移表型和胰島素抵抗呈強正相關。下一代高血壓藥物的發現已經在幾個實驗室進行。每個 96 孔板試劑盒都適用于多達 24 個樣品的三次重復分析。

Detroit R&D生物靶標 14，15-DHET 高血壓酶聯免疫吸附法試劑盒（# DH1）相關研究： 

生物靶標 14，15-DHET 人尿液 ELISA 試劑盒  DH3

用于一步純化的14，15-DHET免疫親和柱  DH31

14，15-EET/DHET 免疫檢測試劑盒  DH2

14，15-脫硫醚活性酶聯免疫吸附試劑盒 SH1

Detroit R&D生物靶標 14，15-DHET 高血壓酶聯免疫吸附法試劑盒部分參考文獻：

1. Kim et al. Four US Patents on hypertension: 6,440,682, 6,534,282, 7,695,927 and 8,409,821.

2. Spiecker et al. Risk of coronary artery disease associated with polymorphism of the cytochrome p450 epoxygenase CYP2J2. Circulation 110, 2132, 2004.

3. Kim et.al. Computational characterization of a series of eicosanoids. Lett. Drug Design & Discovery 2, 322-325. 2005

4. Zhang et.al. Effects of atorvastatin on expression of cytochrome P450 epoxygenase 2C11 in spontaneously hypertensive rats. International Journal of Automation and Computing, 20, 305-311, 2006.

5. Alkayed, et al. Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury. The Journal of Neuroscience, 27(17): 4642-4649, April 25, 2007

Detroit R&D專注于心血管疾病、癌癥的研究，診斷和治療領域。涉及環境健康科學、高血壓、乳腺癌和前列腺癌相關研究領域。艾美捷科技是Detroit R&D的中國代理商，為科研工作者提供優質的產品與服務。